Rankings
▼
Calendar
RCKT Q4 2025 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RCKT
Rocket Pharmaceuticals, Inc.
$572M
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$44M
Net Income
-$43M
EPS (Diluted)
$-0.38
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$35M
Free Cash Flow
-$35M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$330M
Total Liabilities
$53M
Stockholders' Equity
$277M
Cash & Equivalents
$78M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$44M
-$63M
+29.9%
Net Income
-$43M
-$60M
+29.5%
← FY 2025
All Quarters